GD2-NKG2D-aCD73ScFv-CAR NK cells

**GD2-NKG2D-aCD73ScFv-CAR NK cells** are engineered natural killer (NK) cells expressing a chimeric antigen receptor (CAR) construct incorporating targeting domains for GD2 (a disialoganglioside tumor antigen), NKG2D (a receptor recognizing stress-induced ligands on cancer cells), and a single-chain variable fragment (scFv) against CD73 (an ectoenzyme that promotes adenosine-mediated immunosuppression in the tumor microenvironment). This trispecific CAR design enables NK cells to engage multiple tumor-associated targets, enhancing cytotoxicity against solid tumors while countering immunosuppressive mechanisms. The therapy is in early clinical development, primarily for advanced solid malignancies expressing these antigens, with administration typically following lymphodepleting chemotherapy via intravenous infusion; developers include academic institutions focused on cell therapy innovation.